Vanguard Group Inc. Increases Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Vanguard Group Inc. raised its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 41.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,587,804 shares of the company’s stock after acquiring an additional 3,086,311 shares during the period. Vanguard Group Inc. owned about 0.06% of Allogene Therapeutics worth $33,563,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in ALLO. Oppenheimer & Co. Inc. lifted its stake in shares of Allogene Therapeutics by 24.9% in the 1st quarter. Oppenheimer & Co. Inc. now owns 15,050 shares of the company’s stock valued at $137,000 after acquiring an additional 3,000 shares during the last quarter. AlphaCrest Capital Management LLC lifted its position in Allogene Therapeutics by 83.4% in the first quarter. AlphaCrest Capital Management LLC now owns 49,574 shares of the company’s stock valued at $452,000 after purchasing an additional 22,540 shares during the last quarter. MetLife Investment Management LLC lifted its position in Allogene Therapeutics by 58.6% in the first quarter. MetLife Investment Management LLC now owns 36,326 shares of the company’s stock valued at $331,000 after purchasing an additional 13,419 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Allogene Therapeutics by 8.6% during the first quarter. BlackRock Inc. now owns 7,086,233 shares of the company’s stock valued at $64,557,000 after purchasing an additional 560,279 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Allogene Therapeutics by 8.2% in the first quarter. Dimensional Fund Advisors LP now owns 805,987 shares of the company’s stock worth $7,344,000 after purchasing an additional 61,259 shares during the last quarter. 83.63% of the stock is owned by hedge funds and other institutional investors.

Allogene Therapeutics Price Performance

Shares of ALLO opened at $3.99 on Friday. The firm has a market capitalization of $674.68 million, a P/E ratio of -1.91 and a beta of 0.81. Allogene Therapeutics, Inc. has a one year low of $2.23 and a one year high of $6.89. The business has a fifty day moving average of $4.57 and a 200 day moving average of $3.53.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings results on Thursday, March 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.04. Allogene Therapeutics had a negative return on equity of 53.76% and a negative net margin of 202,366.25%. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.05 million. Analysts expect that Allogene Therapeutics, Inc. will post -1.69 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ALLO. JPMorgan Chase & Co. decreased their price objective on shares of Allogene Therapeutics from $9.00 to $8.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 27th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price objective on shares of Allogene Therapeutics in a report on Friday, March 15th. Guggenheim lowered shares of Allogene Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, January 5th. JMP Securities reaffirmed a “market perform” rating on shares of Allogene Therapeutics in a research report on Friday, January 5th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Allogene Therapeutics in a research note on Tuesday, March 19th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, Allogene Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $13.17.

Allogene Therapeutics Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).